<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.3"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Nat Chem</journal-id><journal-id journal-id-type="iso-abbrev">Nat Chem</journal-id><journal-title-group><journal-title>Nature Chemistry</journal-title></journal-title-group><issn pub-type="ppub">1755-4330</issn><issn pub-type="epub">1755-4349</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">10070186</article-id><article-id pub-id-type="pmid">36894702</article-id><article-id pub-id-type="publisher-id">1153</article-id><article-id pub-id-type="doi">10.1038/s41557-023-01153-w</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Unusual peptide-binding proteins guide pyrroloindoline alkaloid formation in crocagin biosynthesis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Adam</surname><given-names>Sebastian</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8639-5864</contrib-id><name><surname>Zheng</surname><given-names>Dazhong</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4808-4691</contrib-id><name><surname>Klein</surname><given-names>Andreas</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7094-5294</contrib-id><name><surname>Volz</surname><given-names>Carsten</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Mullen</surname><given-names>William</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Shirran</surname><given-names>Sally L.</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3363-4168</contrib-id><name><surname>Smith</surname><given-names>Brian O.</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9445-477X</contrib-id><name><surname>Kalinina</surname><given-names>Olga V.</given-names></name><xref ref-type="aff" rid="Aff7">7</xref><xref ref-type="aff" rid="Aff8">8</xref><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1042-5665</contrib-id><name><surname>M&#x000fc;ller</surname><given-names>Rolf</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7153-1365</contrib-id><name><surname>Koehnke</surname><given-names>Jesko</given-names></name><address><email>jesko.koehnke@glasgow.ac.uk</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.11749.3a</institution-id><institution-id institution-id-type="ISNI">0000 0001 2167 7588</institution-id><institution>Workgroup Structural Biology of Biosynthetic Enzymes, </institution><institution>Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI), Saarland University, </institution></institution-wrap>Saarbr&#x000fc;cken, Germany </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.8756.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 2193 314X</institution-id><institution>School of Chemistry, </institution><institution>University of Glasgow, </institution></institution-wrap>Glasgow, UK </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.11749.3a</institution-id><institution-id institution-id-type="ISNI">0000 0001 2167 7588</institution-id><institution>Department of Microbial Natural Products, </institution><institution>HIPS; HZI; Department of Pharmacy, Saarland University, </institution></institution-wrap>Saarbr&#x000fc;cken, Germany </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.8756.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 2193 314X</institution-id><institution>Institute of Cardiovascular and Medical Sciences, </institution><institution>University of Glasgow, </institution></institution-wrap>Glasgow, UK </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.11914.3c</institution-id><institution-id institution-id-type="ISNI">0000 0001 0721 1626</institution-id><institution>Biomedical Sciences Research Complex, </institution><institution>University of St Andrews, </institution></institution-wrap>St Andrews, UK </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.8756.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 2193 314X</institution-id><institution>School of Molecular Biosciences, </institution><institution>University of Glasgow, </institution></institution-wrap>Glasgow, UK </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.11749.3a</institution-id><institution-id institution-id-type="ISNI">0000 0001 2167 7588</institution-id><institution>Drug Bioinformatics Group, </institution><institution>HIPS, HZI, Saarland University, </institution></institution-wrap>Saarbr&#x000fc;cken, Germany </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="GRID">grid.11749.3a</institution-id><institution-id institution-id-type="ISNI">0000 0001 2167 7588</institution-id><institution>Medical Faculty, </institution><institution>Saarland University, </institution></institution-wrap>Homburg, Germany </aff><aff id="Aff9"><label>9</label>Center for Bioinformatics, Saarbr&#x000fc;cken, Germany </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="GRID">grid.452463.2</institution-id><institution>Hannover-Braunschweig Site, </institution><institution>German Centre for Infection Research (DZIF), </institution></institution-wrap>Hanover, Germany </aff></contrib-group><pub-date pub-type="epub"><day>9</day><month>3</month><year>2023</year></pub-date><pub-date pub-type="pmc-release"><day>9</day><month>3</month><year>2023</year></pub-date><pub-date pub-type="ppub"><year>2023</year></pub-date><volume>15</volume><issue>4</issue><fpage>560</fpage><lpage>568</lpage><history><date date-type="received"><day>13</day><month>12</month><year>2021</year></date><date date-type="accepted"><day>27</day><month>1</month><year>2023</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2023</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Ribosomally synthesized and post-translationally modified peptide natural products have provided many highly unusual scaffolds. This includes the intriguing alkaloids crocagins, which possess a tetracyclic core structure and whose biosynthesis has remained enigmatic. Here we use in vitro experiments to demonstrate that three proteins, CgnB, CgnC and CgnE, are sufficient for the production of the hallmark tetracyclic crocagin core from the precursor peptide CgnA. The crystal structures of the homologues CgnB and CgnE reveal them to be the founding members of a peptide-binding protein family and allow us to rationalize their distinct functions. We further show that the hydrolase CgnD liberates the crocagin core scaffold, which is subsequently <italic>N</italic>-methylated by CgnL. These insights allow us to propose a biosynthetic scheme for crocagins. Bioinformatic analyses based on these data led to the discovery of related biosynthetic pathways that may provide access to a structurally diverse family of peptide-derived pyrroloindoline alkaloids.</p><p id="Par2">
<graphic position="anchor" xlink:href="41557_2023_1153_Figa_HTML" id="d32e406"/>
</p></abstract><abstract id="Abs2" abstract-type="web-summary"><p id="Par3">The alkaloids crocagins are derived from a ribosomal peptide through a series of enzymatic post-translational modifications. A combination of biochemistry and structural biology techniques has now been used to elucidate this biosynthetic pathway, propose a mechanism for the formation of the tetracyclic core structure and enable genome mining for related natural products.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Peptides</kwd><kwd>X-ray crystallography</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100010663</institution-id><institution>EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council)</institution></institution-wrap></funding-source><award-id>101002326</award-id><principal-award-recipient><name><surname>Koehnke</surname><given-names>Jesko</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s), under exclusive licence to Springer Nature Limited 2023</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Main</title><p id="Par4">Natural products and their derivatives have been vital for modern medicine and a main contributor to the increase in our quality of life over the past century<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref></sup>. Alkaloids are a profoundly important class of natural products that includes prominent compounds such as morphine and strychnine. A common motif found in alkaloids is the hexahydropyrrolo[2,3-<italic>b</italic>]indole, also referred to as pyrroloindoline. Pyrroloindoline-containing natural products (Fig. <xref rid="Fig1" ref-type="fig">1a</xref>) possess diverse and potent bioactivities, but have presented formidable synthetic challenges<sup><xref ref-type="bibr" rid="CR3">3</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref></sup>. A better understanding of their biosynthesis may advance synthetic efforts or provide semi-synthetic routes to access these valuable molecules. Pyrroloindolines are biosynthetically derived from tryptophan, and different enzymatic routes have been reported. They all result in bond formation between the tryptophan&#x02019;s &#x003b1;-amino group and its indoles&#x02019; C2/&#x003b4;-carbon: in dibrevianamide<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>, naseseazine<sup><xref ref-type="bibr" rid="CR6">6</xref></sup> and (&#x02212;)-ditryptophenaline biosynthesis<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>, P450 enzymes create indole radicals (Supplementary Fig. <xref rid="MOESM1" ref-type="media">1</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><title>Natural products containing pyrroloindoline moieties and the crocagin BGC.</title><p><bold>a</bold>, Structures of the calabar alkaloid (physostigmine) and naseseazine. <bold>b</bold>, Chemical structures of crocagins A (<bold>1</bold>) and B (<bold>2</bold>). <bold>c</bold>, Crocagin BGC found in Chondromyces crocatus CM c5. Genes encoding for putative biosynthetic proteins are shown in orange (dark orange is part of this study); predicted transport proteins, in blue; a regulatory protein, in grey; and the precursor peptide CgnA, in black, which is depicted below the BGC. CgnA is 21 amino acids long and consists of a leader peptide (grey) and a three-amino-acid core peptide (green). Relative sizes of genes and intergenic regions are approximate.</p></caption><graphic xlink:href="41557_2023_1153_Fig1_HTML" id="d32e477"/></fig></p><p id="Par5">In the case of okaramine<sup><xref ref-type="bibr" rid="CR8">8</xref></sup> or himastatin<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>, a flavin-dependent monooxygenase or P450 enzyme, respectively, has been proposed to catalyse the 2,3-epoxidation of the indole, which, after ring-opening of the epoxide, leads to a hydroxylated indole C3 and the formation of the pyrroloindoline (Supplementary Fig. <xref rid="MOESM1" ref-type="media">1</xref>). Finally, enzymatic methylation (cyclic ditryptophan<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>, physostigmine<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>), prenylation (ardeemin<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>, acetylaszonalenin<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>) or farnesylation (drimentine<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>) of the indole C3 can trigger pyrroloindoline formation (Supplementary Fig. <xref rid="MOESM1" ref-type="media">1</xref>).</p><p id="Par6">Ribosomally synthesized and post-translationally modified peptides (RiPPs) are a rapidly growing, major class of natural products and can possess strong and varied bioactivities<sup><xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR16">16</xref></sup>. Their biosynthesis begins with the ribosomal expression of a short gene to yield a precursor peptide that usually consists of an N-terminal &#x02018;leader&#x02019; and a C-terminal &#x02018;core&#x02019; peptide. While the leader peptide is important for substrate recognition by the enzyme(s) installing class-defining modifications, the core peptide is ultimately converted into the final product and can be extensively modified<sup><xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref></sup>. Few pyrroloindoline-containing RiPP classes have been identified to date (for example, omphalotins<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>, ComX<sup><xref ref-type="bibr" rid="CR21">21</xref></sup> and kawaguchipeptin A<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>), and in each case, a prenyltransferase appears to trigger pyrroloindoline formation as described above<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>. Crocagins (<bold>1</bold> and <bold>2</bold>; Fig. <xref rid="Fig1" ref-type="fig">1b</xref>)<sup><xref ref-type="bibr" rid="CR24">24</xref></sup> are very small, intriguing RiPPs that possess a tetracyclic ring system, which consists of a pyrroloindoline fused to a tetrahydropyrimidinone moiety. This rare scaffold, identified during metabolome mining, is thus far unique among RiPPs<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>. While the biosynthetic gene cluster (BGC) for <bold>1</bold> and <bold>2</bold> could be identified<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>, it does not encode for an enzyme previously associated with pyrroloindoline formation. The steps involved in the biosynthesis of <bold>1</bold> and <bold>2</bold> from the precursor peptide CgnA are unknown, as are the functions of the predicted proteins found in their BGC (Fig. <xref rid="Fig1" ref-type="fig">1c</xref>) with the exception of the carbamoyltransferase CgnI<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>. It has been demonstrated that <bold>1</bold> inhibits the highly conserved, key global regulator of the bacterial transcriptome, CsrA, in vitro<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>. CsrA coordinates the expression of a variety of proteins including specific virulence factors as well as biofilm formation and represents a novel target<sup><xref ref-type="bibr" rid="CR25">25</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref></sup>.</p><p id="Par7">We were intrigued by the novelty of the scaffold of <bold>1</bold> and <bold>2</bold> and the possibility of establishing an unprecedented biosynthetic route to peptide-derived pyrroloindoline alkaloids. Here, we demonstrate that four proteins, CgnB, CgnC, CgnD and CgnE, are sufficient to produce the core scaffold of <bold>1</bold> and <bold>2</bold> in vitro and propose a biosynthetic scheme for <bold>1</bold> and <bold>2</bold>. We identify CgnB and CgnE as unusual peptide-binding proteins, which enabled genome mining that led to the in silico discovery of putative related and unrelated biosynthetic pathways.</p></sec><sec id="Sec2" sec-type="results"><title>Results</title><sec id="Sec3"><title>In vitro biosynthesis of the tetracyclic crocagin core</title><p id="Par8">It had been reported that the protein CgnB binds to the precursor peptide CgnA, and that a <italic>cgnB</italic> knockout abolished the production of crocagins A and B<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>. Interestingly, a knockout of the <italic>cgnB</italic> homologue <italic>cgnE</italic> (38% sequence identity; Supplementary Fig. <xref rid="MOESM1" ref-type="media">2</xref>) resulted in a reduction of crocagin production and the detection of two new species: one had a mass suggestive of <bold>1</bold> unmodified at the Trp C&#x003b2; position, while the other agreed with a <italic>des</italic>-<italic>N</italic>-methyl, <italic>des</italic>-carbamoyl <bold>1</bold> (Supplementary Fig. <xref rid="MOESM1" ref-type="media">2</xref>).</p><p id="Par9">To begin our investigation of the biosynthesis of <bold>1</bold> and <bold>2</bold>, we decided to focus on the operon containing <italic>cgnA</italic>, which encodes the precursor peptide CgnA, and putative biosynthetic gene products CgnB, CgnC, CgnD, and CgnE. CgnC was predicted to be a dioxygenase, and the putative esterase CgnD was a likely candidate for leader peptide removal. We thus initially focused on CgnB, CgnC and CgnE. Incubation of CgnA with either CgnB, CgnE or both did not result in any observable product peak (Fig. <xref rid="Fig2" ref-type="fig">2a</xref> and Supplementary Fig. <xref rid="MOESM1" ref-type="media">3</xref>). Expression of CgnC required the use of an alternative, upstream start codon (Supplementary Fig. <xref rid="MOESM1" ref-type="media">4</xref>), and incubation with CgnA did not lead to observable product formation, unless FeCl<sub>2</sub>, ascorbic acid and &#x003b1;-ketoglutarate were added (Fig. <xref rid="Fig2" ref-type="fig">2a</xref> and Supplementary Fig. <xref rid="MOESM1" ref-type="media">5</xref>). The addition of these cofactors, always implied in CgnC reactions from this point forward, yielded a new peak with a mass suggestive of hydroxylation (+16&#x02009;Da), but the predominant peak remained unmodified CgnA (Fig. <xref rid="Fig2" ref-type="fig">2a</xref> and Supplementary Fig. <xref rid="MOESM1" ref-type="media">5</xref>). The addition of CgnE to CgnA&#x02013;CgnC led to the formation of an additional, minor peak with a mass shift of +28&#x02009;Da, which could indicate two oxidation events, for example, oxidation to ketones at the C&#x003b2; atoms of the Tyr and Trp residues of the core peptides (Fig. <xref rid="Fig2" ref-type="fig">2a</xref> and Supplementary Fig. <xref rid="MOESM1" ref-type="media">5</xref>). Intriguingly, the addition of the CgnE homologue CgnB led to a different result, with two additional product peaks detected when compared to CgnA&#x02013;CgnE or CgnA&#x02013;CgnC reactions (Fig. <xref rid="Fig2" ref-type="fig">2a</xref> and Supplementary Fig. <xref rid="MOESM1" ref-type="media">5</xref>). One of these had a mass shift of +14&#x02009;Da, which could indicate the formation of the tetracyclic core structure (<bold>3a</bold>; Fig. <xref rid="Fig2" ref-type="fig">2a</xref> and Supplementary Fig. <xref rid="MOESM1" ref-type="media">5</xref>). These data agree with the knockout studies, where the inactivation of <italic>cgnE</italic> led to reduced product formation, while the inactivation of <italic>cgnB</italic> abolished the production of <bold>1</bold> and <bold>2</bold>. The addition of both CgnB and CgnE to CgnA&#x02013;CgnC reactions had a profound effect and led to the formation of a major product with high turnover (Fig. <xref rid="Fig2" ref-type="fig">2a</xref> and Supplementary Fig. <xref rid="MOESM1" ref-type="media">5</xref>). This product, <bold>3a</bold>, had a mass shift of +14&#x02009;Da, the same retention time as that observed for the +14&#x02009;Da product of CgnA&#x02013;CgnB&#x02013;CgnC reactions, and lost its UV absorption at 280&#x02009;nm, implying loss of aromaticity of the Trp side chain (Supplementary Fig. <xref rid="MOESM1" ref-type="media">5</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><title>In vitro biosynthesis of the crocagin core structure.</title><p><bold>a</bold>, Extracted ion chromatograms (EICs) of CgnA (magenta) and reactions of CgnA with CgnB and CgnE; CgnC; CgnB and CgnC; CgnC and CgnE; or CgnB, CgnC and CgnE (from top left to right). Addition of CgnC with cofactors to CgnA triggered the formation of a minor +16&#x02009;Da species (green). Adding CgnA to CgnB, CgnE and CgnC with cofactors resulted in the consumption of CgnA (magenta) and the formation of a major product (+14&#x02009;Da, blue) as well as minor products (+16&#x02009;Da, green; +30&#x02009;Da (a and b are peaks of the same mass, but with different retention times), orange). All EICs reflect the +5 charge state of CgnA (mutants) and products &#x000b1;0.01&#x02009;Da. Representative experiments were repeated independently at least three times with similar results. Details can be found in Supplementary Fig. <xref rid="MOESM1" ref-type="media">5</xref>. <bold>b</bold>, NMR structure of <bold>3a</bold>.</p></caption><graphic xlink:href="41557_2023_1153_Fig2_HTML" id="d32e773"/></fig></p><p id="Par10">Tandem mass spectrometry (MS<sup>2</sup>) of the +16&#x02009;Da species suggested hydroxylation of the core peptide&#x02019;s Trp (Supplementary Fig. <xref rid="MOESM1" ref-type="media">6</xref>). MS<sup>2</sup> of the +28&#x02009;Da species was not possible due to low abundance, but MS<sup>2</sup> of the +30&#x02009;Da peak placed +14&#x02009;Da on the core peptide&#x02019;s Tyr (keto group) and +16&#x02009;Da on the core peptide&#x02019;s Trp residue (hydroxylation; Supplementary Fig. <xref rid="MOESM1" ref-type="media">6</xref>). We were able to identify a low abundance +32&#x02009;Da species, and, as expected, MS<sup>2</sup> analysis placed hydroxylations on the core peptide&#x02019;s Tyr and Trp (Supplementary Fig. <xref rid="MOESM1" ref-type="media">6</xref>). All mass errors can be found in Supplementary Table <xref rid="MOESM4" ref-type="media">1</xref>. A minor product with a mass shift of +12&#x02009;Da, <bold>3b</bold>, was also observed. We reasoned that this could be an intermediate towards <bold>2</bold>, with a mass of &#x02013;2&#x02009;Da compared to crocagin A due to its additional double bond (Supplementary Fig. <xref rid="MOESM1" ref-type="media">5</xref>). NMR analysis of <bold>3a</bold> confirmed the presence of the hexahydropyrrolo[2,3-<italic>b</italic>]indole fused to a tetrahydropyrimidinone moiety (Fig. <xref rid="Fig2" ref-type="fig">2b</xref> and Supplementary Table <xref rid="MOESM1" ref-type="media">2</xref>) and thus the successful in vitro biosynthesis of the tetracyclic crocagin core.</p></sec><sec id="Sec4"><title>CgnB and CgnE may have evolved from Zn<sup>2+</sup>-dependent aminopeptidases</title><p id="Par11">We were very intrigued by the different behaviour of the homologues CgnB and CgnE in biochemical assays. CgnB and CgnE did not show similarity to any family in the Pfam database, and a sequence-based search using the HHpred server<sup><xref ref-type="bibr" rid="CR28">28</xref></sup> returned only three hits with more than 50% sequence coverage, which were aminopeptidases (Pfam family Peptidase_M29). We did not observe aminopeptidase activity, and the sequence identities of CgnB and CgnE with the aminopeptidases were &#x0003c;25% (Supplementary Fig. <xref rid="MOESM1" ref-type="media">7</xref>). It was thus apparent that structural information would be valuable to better characterize these two proteins. First, the structure of CgnE was determined to 2.0&#x02009;&#x000c5; (Fig. <xref rid="Fig3" ref-type="fig">3a</xref> and Supplementary Fig. <xref rid="MOESM1" ref-type="media">8</xref>). Details for all reported protein structures can be found in the experimental section, and all data collection and refinement statistics can be found in Supplementary Table <xref rid="MOESM1" ref-type="media">3</xref>.<fig id="Fig3"><label>Fig. 3</label><caption><title>Structures of CgnB and CgnE, affinity measurements and genome mining.</title><p><bold>a</bold>, Overall structure of CgnE. Cartoon representation using the rainbow colour scheme (N terminus, blue; to C terminus, red). <bold>b</bold>, Metal binding site found in CgnB (yellow) and CgnE (cyan). Two key residues are mutated in CgnE (Glu to Lys and His to Tyr). Zn<sup>2+</sup> ions are numbered <bold>1</bold> and <bold>2</bold>. <bold>c</bold>, Table of affinities to investigate substrate binding and complex formation. Components following the &#x02018;+&#x02019; are titrated, while the other components are held constant. Representative experiments were repeated independently three times with similar results. <bold>d</bold>, Sequence of CgnA with residues numbered. Positively charged side chains are highlighted in blue, while the core peptide is in grey. <bold>e</bold>, Representatives of the five distinct BGC types identified. Common genes are colour-coded. White arrows represent genes with functions not found in all clusters. ABC, ATP-binding cassette; MFS, major facilitator superfamily. Details are reported in Supplementary Tables <xref rid="MOESM1" ref-type="media">4</xref> and <xref rid="MOESM1" ref-type="media">5</xref>.</p></caption><graphic xlink:href="41557_2023_1153_Fig3_HTML" id="d32e888"/></fig></p><p id="Par12">CgnB was recalcitrant to crystallization until a slight molar excess of CgnA was added prior to crystallization trials. We determined the CgnB structure to 2.3&#x02009;&#x000c5; resolution but observed no electron density for CgnA, so the peptide may simply have acted as an additive to promote crystallization. As expected for homologous proteins, the C&#x003b1; root-mean-square deviation (r.m.s.d.) between the structures of CgnB and CgnE was only 1.2&#x02009;&#x000c5; over 284 residues (Supplementary Fig. <xref rid="MOESM1" ref-type="media">9</xref>). Curiously, CgnB contained a dinuclear metal centre that was partially occupied. The CheckMyMetal validation server<sup><xref ref-type="bibr" rid="CR29">29</xref></sup> suggested that either Zn<sup>2+</sup> or Co<sup>2+</sup> could be bound and inductively coupled plasma mass spectrometry (ICP-MS) identified the metals as zinc, with only traces of cobalt found (Supplementary Fig. <xref rid="MOESM1" ref-type="media">10</xref>). The binding sites comprised CgnB residues Glu161, Glu252 (shared between Zn<sup>2+</sup>
<bold>1</bold> and <bold>2</bold>), Glu274 and His280 (Zn<sup>2+</sup>
<bold>1</bold>) and His291 and Asp293 (Zn<sup>2+</sup>
<bold>2</bold>; Fig. <xref rid="Fig3" ref-type="fig">3b</xref> and Supplementary Fig. <xref rid="MOESM1" ref-type="media">10</xref>). In CgnE, the metal binding site of Zn<sup>2+</sup>
<bold>1</bold> was disrupted by mutations in two metal-coordinating residues (CgnB numbering), Glu274Lys and His280Tyr, and no density for metal ions was observed in the CgnE structure (Fig. <xref rid="Fig3" ref-type="fig">3b</xref> and Supplementary Fig. <xref rid="MOESM1" ref-type="media">10</xref>). To exclude the possibility that CgnE may bind Fe<sup>2+</sup>, which is added as a CgnC cofactor to the reactions and could be oxidized and released from CgnE before structure determination, we incubated the protein with a large excess of fresh FeCl<sub>2</sub> and processed the sample immediately for analysis by ICP-MS. No iron could be detected (Supplementary Fig. <xref rid="MOESM1" ref-type="media">10</xref>).</p><p id="Par13">A search for structural homologues of CgnB and CgnE using the DALI server<sup><xref ref-type="bibr" rid="CR30">30</xref></sup> returned only three viable hits, which concurred with the sequence-based results obtained from HHpred<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>: aminopeptidase T (Protein Data Bank (PDB) no. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2210/pdb2ayi/pdb">2ayi</ext-link>), aminopeptidase PepS (PDB no. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2210/pdb4ics/pdb">4ics</ext-link>) and aminopeptidase AMPS (PDB no. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2210/pdb1zjc/pdb">1zjc</ext-link>), which are structural homologues (C&#x003b1; r.m.s.d. 4ics/1zjc&#x02009;=&#x02009;2.2&#x02009;&#x000c5;; C&#x003b1; r.m.s.d. 4ics/2ayi&#x02009;=&#x02009;4.3&#x02009;&#x000c5; over &#x0003e;90% of residues; Supplementary Fig. <xref rid="MOESM1" ref-type="media">10</xref>). The key difference between CgnB or CgnE and the aminopeptidases was found in the N-terminal portions of the proteins (Supplementary Fig. <xref rid="MOESM1" ref-type="media">11</xref>). The aminopeptidases form an extensive dimer interface, and the residues involved in its formation are largely missing in CgnB and CgnE, which rationalizes their monomeric state in the crystals. All three aminopeptidases harbour dinuclear metal centres in the same position as CgnB and contain either Zn<sup>2+</sup> or Co<sup>2+</sup>. To test the effect of different metal ions on the reaction among CgnA, CgnB, CgnC and CgnE, we dialysed CgnB extensively with ethylenediaminetetraacetic acid and reduced the Zn<sup>2+</sup> concentration to background (buffer) levels (Supplementary Fig. <xref rid="MOESM1" ref-type="media">10</xref>). Unfortunately, the protein denatured in the process, and activity could not be restored.</p></sec><sec id="Sec5"><title>Inference of protein complex formation between CgnB, CgnC and CgnE</title><p id="Par14">The requirement for all three components&#x02014;CgnB, CgnC and CgnE&#x02014;to be present for efficient catalysis of the formation of <bold>3a</bold> or <bold>3b</bold> implied that the proteins may interact. We probed each protein&#x02019;s ability to bind the substrate CgnA by microscale thermophoresis (MST) and found that CgnB and CgnE, but not CgnC, were able to bind CgnA (Fig. <xref rid="Fig3" ref-type="fig">3c</xref> and Supplementary Fig. <xref rid="MOESM1" ref-type="media">12</xref>). The equilibrium dissociation constant (<italic>K</italic><sub>D</sub>) of 10.5&#x02009;&#x000b5;M for the CgnA&#x02013;CgnB interaction is approximately one order of magnitude lower than that measured by surface plasmon resonance<sup><xref ref-type="bibr" rid="CR24">24</xref></sup> and five times weaker than the one we determined for the CgnA&#x02013;CgnE interaction (1.8&#x02009;&#x000b5;M; Fig. <xref rid="Fig3" ref-type="fig">3c</xref>). When we investigated the binding of the homologues CgnB and CgnE to CgnC, we found the CgnE&#x02013;CgnC <italic>K</italic><sub>D</sub> to be ~1&#x02009;&#x000b5;M (Fig. <xref rid="Fig3" ref-type="fig">3c</xref> and Supplementary Fig. <xref rid="MOESM1" ref-type="media">13</xref>). The CgnB&#x02013;CgnC <italic>K</italic><sub>D</sub> was weaker (~6&#x02009;&#x000b5;M), and no interaction could be detected for CgnB&#x02013;CgnE (Fig. <xref rid="Fig3" ref-type="fig">3c</xref> and Supplementary Fig. <xref rid="MOESM1" ref-type="media">13</xref>). We wondered if the presence of CgnA would change this behaviour and determined the <italic>K</italic><sub>D</sub> of CgnC to CgnB in the presence of CgnA (400&#x02009;&#x000b5;M). The effect was an ~60-fold improved affinity to ~100&#x02009;nM (Fig. <xref rid="Fig3" ref-type="fig">3c</xref> and Supplementary Fig. <xref rid="MOESM1" ref-type="media">13</xref>). Addition of CgnA (400&#x02009;&#x000b5;M) to CgnC&#x02013;CgnE had very little effect (2-fold increase) on the CgnC&#x02013;CgnE affinity (Fig. <xref rid="Fig3" ref-type="fig">3c</xref> and Supplementary Fig. <xref rid="MOESM1" ref-type="media">14</xref>). It therefore appeared that CgnB and CgnE might be recruiting the substrate CgnA to CgnC. When we analysed the binding of CgnA to CgnB in the presence of a large excess of CgnE (250&#x02009;&#x000b5;M), we did not observe binding (Fig. <xref rid="Fig3" ref-type="fig">3c</xref> and Supplementary Fig. <xref rid="MOESM1" ref-type="media">13</xref>). This implied that CgnB and CgnE cannot bind simultaneously to the same substrate molecule. To support our MST data, we attempted pull-down assays. While these confirmed the interactions between CgnA and CgnB or CgnE, we could not find conditions that prevented CgnC from binding non-specifically to resin materials. The same was observed for surface plasmon resonance measurements (Supplementary Fig. <xref rid="MOESM1" ref-type="media">13</xref>).</p><p id="Par15">Size-exclusion chromatography data suggested that CgnB and CgnE were monomers in solution (as observed in the crystal structures), while CgnC was a dimer (Supplementary Fig. <xref rid="MOESM1" ref-type="media">13</xref>). Unfortunately, putative CgnB&#x02013;CgnC&#x02013;CgnE complexes were unstable in size-exclusion chromatography, and experiments to stabilize them for structure elucidation and detailed mechanistic studies are currently underway. The question we then asked was whether binding of CgnB and CgnE would occur at the same binding site on CgnC, as might be expected for homologues. We thus determined the affinity of CgnB&#x02013;CgnC in the presence of a constant, large excess (250&#x02009;&#x000b5;M) of CgnE. We obtained a <italic>K</italic><sub>D</sub> of 28&#x02009;&#x000b5;M, which was approximately five times weaker than in the absence of CgnE, but these data still suggested that CgnB and CgnE can concurrently bind to CgnC (Supplementary Fig. <xref rid="MOESM1" ref-type="media">13</xref>). Taken together, our data imply that a complex may form during crocagin biosynthesis. If CgnC bound CgnB and CgnE at the same time, as MST measurements suggest it could, the dimeric nature of CgnC would likely result in a complex with the stoichiometry CgnB<sub>2</sub>/CgnC<sub>2</sub>/CgnE<sub>2</sub> and have the ability to bind up to four CgnA molecules.</p></sec><sec id="Sec6"><title>Genome mining using CgnB and CgnE reveals crocagin-like BGCs</title><p id="Par16">The unique features of CgnB and CgnE prompted us to investigate their evolution. Sequence similarity searches in bacterial whole-genome sequencing contigs revealed that CgnB and CgnE homologues can be found in ~100 genomes from Actinobacteria, Cyanobacteria, Betaproteobacteria, Gammaproteobacteria and Deltaproteobacteria. In all cases, the similarity stretched over almost the entire protein length, and the homologues did not contain any additional domains, which makes CgnB and CgnE the founding members of a new protein family.</p><p id="Par17">In all genomes containing only one copy of a CgnB or CgnE homologue, the metal binding site was intact, despite an overall low sequence identity (between 21% and 42%). Finding two CgnB and/or CgnE homologues in the same genomic contig was much rarer (Supplementary Table <xref rid="MOESM1" ref-type="media">4</xref>), and in all cases, these two copies lie at a distance &#x0003c;2.1&#x02009;kbp. To investigate the evolution of the duplicated CgnB and CgnE homologues, we constructed a bootstrapped maximum likelihood phylogenetic tree (Supplementary Fig. <xref rid="MOESM1" ref-type="media">14</xref> and <xref rid="MOESM1" ref-type="media">Supplementary Information</xref>). Low bootstrap values did not allow many internal branches to be resolved with certainty, but it appears probable that three to five duplication events occurred during the evolution of this protein family. In every case, the second copy of the protein acquired deleterious mutations in the metal binding site that were different in each case. Mutations designed to restore metal binding in CgnE or disrupt metal binding in CgnB led to insoluble protein for all mutations tested. It is remarkable that at least three duplication events happened independently, which may be a sign of strong evolutionary pressure to acquire a second, mutated copy of the protein.</p><p id="Par18">Genome mining for novel RiPPs using instances of a single copy of CgnB or CgnE with the program RiPPER<sup><xref ref-type="bibr" rid="CR31">31</xref></sup> resulted in the discovery of a number of putative precursor peptides (<xref rid="MOESM3" ref-type="media">Supplementary Data</xref>), which were used to create a sequence similarity network (Supplementary Fig. <xref rid="MOESM1" ref-type="media">15</xref>). In genomic contigs harbouring two CgnB or CgnE copies, we searched for a potential precursor and were able to find a candidate within &#x0003c;1.5&#x02009;kbp in all cases (Supplementary Table <xref rid="MOESM1" ref-type="media">4</xref>). Aligning these candidate peptides at their C termini revealed a strong conservation pattern for the Tyr and Trp positions of the core peptide (Ile-Tyr-Trp for crocagin; Supplementary Table <xref rid="MOESM1" ref-type="media">4</xref>). The Ile position is variable, and we found an Ile to Gly mutation to be a very good substrate for CgnB, CgnC or CgnE (Supplementary Fig. <xref rid="MOESM1" ref-type="media">16</xref>). Two other single leader peptide point mutations in highly conserved positions also had no effect on processing (Lys2Glu and Gly17Phe; Supplementary Fig. <xref rid="MOESM1" ref-type="media">16</xref>).</p><p id="Par19">The leader peptide is enriched with positively charged amino acids, and both CgnB and CgnE show a large, strongly negatively charged patch near the possible binding site (Supplementary Fig. <xref rid="MOESM1" ref-type="media">16</xref>). Of the six positively charged residues in the 18-amino-acid-long CgnA leader peptide (CgnA<sup>LP</sup>), three are found in the N-terminal half, while the other three are close to the core peptide (Fig. <xref rid="Fig3" ref-type="fig">3d</xref>). Deleting residues 1&#x02013;5 of CgnA (and thus two lysines; Fig. <xref rid="Fig3" ref-type="fig">3d</xref>) had no effect on turnover, but removing residues 1&#x02013;10, which include a third lysine, abolished processing (Supplementary Fig. <xref rid="MOESM1" ref-type="media">17</xref>). To analyse the importance of the positively charged residues, we reacted a CgnA variant with the three N-terminal lysines mutated to alanine (CgnA<sup>N3A</sup>; Lys2Ala, Lys3Ala and Lys6Ala) with CgnBCgnC&#x02013;CgnE and found the reaction to be somewhat impaired (Supplementary Fig. <xref rid="MOESM1" ref-type="media">17</xref>). Exchanging the three C-terminal positively charged residues to alanine (CgnA<sup>C3A</sup>; Arg13Ala, Lys15Ala and Lys16Ala), on the other hand, severely reduced product formation (Supplementary Fig. <xref rid="MOESM1" ref-type="media">17</xref>). These data imply that essential CgnA residues for substrate recognition are located after position five and include four positively charged residues.</p><p id="Par20">The structures of the putative crocagin-like BGCs identified here differ in all genomes, but one can identify five key architectures (Fig. <xref rid="Fig3" ref-type="fig">3e</xref>). The crocagin BGC is an outlier, and intriguingly all other clusters contain a predicted glycosyltransferase instead of the carbamoyltransferase present in the crocagin BGC. This suggests that crocagin-like natural products may be glycosylated, which has thus far been a very rare modification in RiPPs. Some BGCs contain a predicted decarboxylase, which may remove the negative charge of crocagin-like molecules and thus improve membrane permeability in addition to providing biosynthetic access to new structural variants.</p></sec><sec id="Sec7"><title>Protease CgnD releases the crocagin core scaffold</title><p id="Par21">The product of the CgnB&#x02013;CgnC&#x02013;CgnE reaction, <bold>3a</bold>, contained the crocagin tetracyclic ring system, and we thus suspected that proteolytic removal of the leader peptide by CgnD might be possible. When CgnD was added to the product of CgnA&#x02013;CgnB&#x02013;CgnC&#x02013;CgnE reactions containing <bold>3a</bold> and <bold>3b</bold>, we observed the slow production of <bold>4a</bold> ([M]<sup>+</sup> calculated, 495.2238; observed, 495.2239; mass error (<italic>&#x00394;</italic>)&#x02009;=&#x02009;0.2&#x02009;ppm), which represents the crocagin core scaffold (<italic>des</italic>-methyl and <italic>des</italic>-carbamoyl) and also corresponds to the mass produced by the <italic>cgnE</italic> knockout (Fig. <xref rid="Fig4" ref-type="fig">4a</xref> and Supplementary Figs. <xref rid="MOESM1" ref-type="media">2</xref> and <xref rid="MOESM1" ref-type="media">18</xref>). Interestingly, we again observed a minor peak of &#x02013;2&#x02009;Da (<bold>4b</bold>; [M]<sup>+</sup> calculated, 493.2082; observed, 493.2083; <italic>&#x00394;</italic>&#x02009;=&#x02009;0.2&#x02009;ppm), which may be the core scaffold of crocagin B (Supplementary Fig. <xref rid="MOESM1" ref-type="media">18</xref>). Slow proteolytic processing of modified precursor peptides has been observed in a number of RiPP biosynthetic pathways and may be linked to biosynthetic timing<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>. In an attempt to accelerate the production of <bold>4a</bold>, we replaced the Asn residue preceding the core peptide with a Lys. This mutant was a very poor substrate for CgnB&#x02013;CgnC&#x02013;CgnE, possibly because the introduced positive charge interfered with native substrate binding. The addition of trypsin did lead to the formation of traces of <bold>4a</bold> (Supplementary Fig. <xref rid="MOESM1" ref-type="media">18</xref>). Rapid production of crocagin-like molecules will thus require the selection of alternative proteases or enzyme engineering of CgnD. To rationalize the slow turnover, we attempted to determine the affinity of CgnD for <bold>3a</bold>, CgnA and the leader peptide, but were unable to detect binding by microscale thermophoresis (Supplementary Fig. <xref rid="MOESM1" ref-type="media">19</xref>). We hoped that the crystal structure of CgnD might yield additional insights and determined the structure to 2.35&#x02009;&#x000c5; resolution (Supplementary Fig. <xref rid="MOESM1" ref-type="media">20</xref>). The two protomers found in the asymmetric unit form an intricate dimer interface (Supplementary Table <xref rid="MOESM1" ref-type="media">6</xref>), which is unlike that of the closest structural homologues identified by a Dali server<sup><xref ref-type="bibr" rid="CR30">30</xref></sup> search. Intriguingly, it appeared as if the dimer provides two antiparallel channels for substrate binding that terminated at the respective active sites (Fig. <xref rid="Fig4" ref-type="fig">4b</xref>). The catalytic triad comprised Asp325, His328 and Ser79, and the distance observed between the Asp325 atom O&#x003b4;2 and His328 atom H&#x003b4;2 was within the expected range (1.8&#x02009;&#x000c5;). The distance between His328 atom N&#x003b5;2 and Ser79 atom H&#x003b3; could not be determined because a sulfate ion was bound at the active site, which led to a rotation of the Ser side chain. Removal of the sulfate in silico and subsequent rotation of the Ser side chain did not allow the distance to decrease below 2.8&#x02009;&#x000c5; (Supplementary Fig. <xref rid="MOESM1" ref-type="media">20</xref>). The resulting lack of nucleophilicity appeared a probable cause for the slow turnover and was supported by our inability to label CgnD with phenylmethylsulfonyl fluoride (Supplementary Fig. <xref rid="MOESM1" ref-type="media">20</xref>). This situation is reminiscent of PatA from the patellamide pathway, which also turns over very slowly<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>.<fig id="Fig4"><label>Fig. 4</label><caption><title>Processing of 3a and 3b by CgnD and CgnL.</title><p><bold>a</bold>, In vitro biosynthesis of the crocagin A core scaffold, <bold>4a</bold>, using CgnD. <italic>m/z</italic> represents mass divided by charge number and the horizontal axis in a mass spectrum is expressed in units of <italic>m/z</italic>. <bold>b</bold>, Surface representation of the CgnD dimer. Active sites are highlighted by dashed boxes. <bold>c</bold>, <italic>N</italic>-methylation of <bold>4a</bold> by CgnL to yield <bold>5a</bold>. <bold>d</bold>, Cartoon representation of the CgnL structure. <italic>S</italic>-adenosylhomocysteine is shown as black sticks. Details of <bold>a</bold> and <bold>c</bold> can be found in Supplementary Figs. <xref rid="MOESM1" ref-type="media">18</xref> and <xref rid="MOESM1" ref-type="media">21</xref>. Representative experiments were repeated independently at least three times with similar results.</p></caption><graphic xlink:href="41557_2023_1153_Fig4_HTML" id="d32e1337"/></fig></p></sec><sec id="Sec8"><title><italic>N</italic>-methylation of 4a and 4b is catalysed by CgnL</title><p id="Par22">The final unresolved step in the biosynthesis of <bold>1</bold> and <bold>2</bold> was the <italic>N</italic>-methylation of <bold>4a</bold> and <bold>4b</bold>, as the carbamoyltransferase function of CgnI had been determined previously<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>. Based on sequence alignments, CgnL, named &#x02018;MT&#x02019; in the original crocagin publication<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>, was the likely candidate. Indeed, incubation of <bold>4a</bold> and <bold>4b</bold> with CgnL and <italic>S</italic>-adenosylmethionine led to the formation of <bold>5a</bold> ([M]<sup>+</sup> calculated, 509.2395; observed, 509.2391; <italic>&#x00394;</italic>&#x02009;=&#x02009;&#x02013;0.8&#x02009;ppm) and the &#x02013;2&#x02009;Da <bold>5b</bold> ([M]<sup>+</sup> calculated, 507.2238; observed, 507.2239; <italic>&#x00394;</italic>&#x02009;=&#x02009;0.2&#x02009;ppm; Fig. <xref rid="Fig4" ref-type="fig">4c</xref> and Supplementary Fig. <xref rid="MOESM1" ref-type="media">21</xref>). The mass increase of +14&#x02009;Da suggested methylation and thus the production of <italic>des</italic>-carbamoyl <bold>1</bold> and <bold>2</bold>.</p><p id="Par23">The crystal structure of CgnL in complex with <italic>S</italic>-adenosylhomocysteine was determined to a resolution of 1.96&#x02009;&#x000c5; and appeared monomeric, which was consistent with the closest structural homologues of CgnL identified in a Dali search<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>. The overall shape of CgnL was typical for class I <italic>S</italic>-adenosylmethionine-dependent methyltransferases with a Rossman fold (Fig. <xref rid="Fig4" ref-type="fig">4d</xref> and Supplementary Fig. <xref rid="MOESM1" ref-type="media">22</xref>). The electron density for <italic>S</italic>-adenosylhomocysteine was unambiguous as expected for a well-coordinated ligand (Supplementary Fig. <xref rid="MOESM1" ref-type="media">22</xref>). Interestingly, the closest structural homologues with a defined function are involved in natural product biosynthetic pathways: CcbJ (PDB no. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2210/pdb4hh4/pdb">4hh4</ext-link>) <italic>N</italic>-methylates the antibiotic celesticetin<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>, while KedS8 (PDB no. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2210/pdb5bsz/pdb">5bsz</ext-link>) <italic>N</italic>-methylates the chromophore of the anticancer chromoprotein kedaricidin<sup><xref ref-type="bibr" rid="CR34">34</xref></sup>.</p></sec><sec id="Sec9"><title>A proposed mechanism for the biosynthesis of 3a and 3b</title><p id="Par24">The precise molecular mechanism of the initial step in crocagin biosynthesis, leading to the formation of <bold>3a</bold> and <bold>3b</bold>, will require further study. We favour the following sequence of events based on the knockout, biochemical and binding data (Fig. <xref rid="Fig5" ref-type="fig">5a</xref>): CgnA binds to CgnE, which may either be part of a CgnC&#x02013;CgnE complex, or bind to CgnC after binding CgnA. We found the binding of CgnE to the CgnA<sup>LP</sup> to be almost 300 times weaker than binding to CgnA (<italic>K</italic><sub>D</sub>&#x02009;=&#x02009;514&#x02009;&#x000b5;M; Supplementary Fig. <xref rid="MOESM1" ref-type="media">23</xref>). The main driver for binding thus appears to be the core peptide, and it is tempting to suggest that CgnE&#x02019;s role may be to recruit the substrate peptide to CgnC and present the core peptide in a particular way that enables or accelerates correctly timed catalysis. This would agree with our knockout and in vitro biochemical data, which show that the presence of CgnE without CgnB does not enable formation of the crocagin core structure. When we tested the mutant CgnA Y20F, we could only detect trace amounts of a +14&#x02009;Da species, and the major product peak had a mass increase of 16&#x02009;Da. (Supplementary Fig. <xref rid="MOESM1" ref-type="media">23</xref>). Unlike the +16&#x02009;Da product of a CgnA&#x02013;CgnC&#x02013;CgnE reaction (Trp hydroxylation; Supplementary Fig. <xref rid="MOESM1" ref-type="media">6</xref>), MS<sup>2</sup> analysis of this intermediate revealed a mixture with hydroxylation of either Phe or Trp (Supplementary Fig. <xref rid="MOESM1" ref-type="media">24</xref>). Hydroxylation at the Tyr20 C&#x003b2; position allows CgnB to catalyse an elimination reaction via its bound Zn<sup>2+</sup> (or Co<sup>2+</sup>) ions, which results in a double bond between the Tyr20 C&#x003b1; and C&#x003b2; atoms, creating a conjugated amine. The transition state, in which the Tyr20 C&#x003b1; hydrogen would possess a lowered p<italic>K</italic><sub>a</sub>, could be stabilized by the Tyr side chain, rationalizing why a Tyr20Phe mutation is detrimental to turnover (Supplementary Fig. <xref rid="MOESM1" ref-type="media">23</xref>). Tyr20 then undergoes conjugate addition with the Trp21 indole nitrogen, and subsequent proton transfer completes the first ring-forming reaction. The second ring-closure reaction between the Trp &#x003b1;-nitrogen and &#x003b4;<sub>1</sub> carbon atom could then occur spontaneously to complete the formation of the tetracyclic ring system. It is unclear at which point hydroxylation of the Trp21 C&#x003b2; position occurs, but the inferred biosynthetic complex would enable fast transfer from one substrate binding site to the next. Interestingly, CgnA binding by CgnB is not dependent on the core peptide to the same extent as observed for CgnE, with an 8-fold reduction in affinity for CgnA<sup>LP</sup> compared to CgnA (Supplementary Fig. <xref rid="MOESM1" ref-type="media">23</xref>).<fig id="Fig5"><label>Fig. 5</label><caption><title>Biosynthetic proposal leading to the formation of crocagins A (1) and B (2).</title><p><bold>a</bold>, Proposed mechanism for installation of the tetracyclic crocagin core. <bold>b</bold>, CgnB, CgnC and CgnE install two &#x003b2;-hydroxylations and facilitate the two ring-closure reactions. CgnD cleaves the core scaffold off the leader peptide, which is subsequently methylated and carbamoylated. Crocagin B, the low abundance crocagin in extracts from the natural producer, appears to originate from oxidation before ring closure during the biosynthesis of <bold>3a</bold> to yield <bold>3b</bold>.</p></caption><graphic xlink:href="41557_2023_1153_Fig5_HTML" id="d32e1547"/></fig></p><p id="Par25">It has been observed in a number of RiPP systems that the leader peptide can activate the processing enzymes when it is supplied <italic>in trans</italic><sup><xref ref-type="bibr" rid="CR35">35</xref></sup>. This was not the case for CgnB&#x02013;CgnC&#x02013;CgnE reactions, where turnover of the core peptide was marginal when the leader peptide was added <italic>in trans</italic> (Supplementary Fig. <xref rid="MOESM1" ref-type="media">23</xref>). This suggests that a physical connection between leader and core peptide is essential for catalysis, perhaps to enable efficient transfer of the substrate between CgnE and CgnB.</p></sec></sec><sec id="Sec10" sec-type="discussion"><title>Discussion</title><p id="Par26">It is intriguing to see how the world of small alkaloids merges with that of ribosomal natural products. The recent discovery that the pyrroloquinoline alkaloids ammosamides are in fact RiPPs<sup><xref ref-type="bibr" rid="CR36">36</xref></sup> and crocagins may just be the beginning. We propose the following biosynthetic scheme for crocagins (Fig. <xref rid="Fig5" ref-type="fig">5b</xref>): After expression of CgnA, the precursor peptide is processed by the proteins CgnB, CgnC and CgnE and undergoes hydroxylation at the Tyr20 and Trp21 C&#x003b2; positions, which triggers the two ring-closing reactions. It is possible that pyrroloindoline formation is the first ring-closure reaction, but we think that the seeming absence of an indole &#x02018;activator&#x02019; (for example, C3 prenylation; Supplementary Fig. <xref rid="MOESM1" ref-type="media">1</xref>) and the disfavoured nature of 5-<italic>endo</italic>-trig ring-forming reactions makes it more likely that the pyrroloindoline forms second. In a small fraction of CgnA, the hydroxylated Tyr20 C&#x003b2; is oxidized to the ketone, which results in a double bond between the Tyr20 C&#x003b1; and C&#x003b2; upon ring closure and thus ultimately the formation of <bold>2</bold>. This reaction would not be catalysed by CgnB, but rather be spontaneous and slow. In our view, it is likely that the observed CgnA +28&#x02009;Da peak is a shunt product and an artefact of a system missing either CgnB or CgnE. It is unclear if the CgnA +16&#x02009;Da peak is a shunt product or true intermediate, because we do not observe it when CgnB and CgnE are both present. The +30&#x02009;Da peak, which we observe only in reactions where <bold>3a</bold> and <bold>3b</bold> are formed, appears to be an intermediate towards <bold>2</bold>, because MS<sup>2</sup> analysis placed the keto group on the core peptide&#x02019;s Tyr, while the Trp is hydroxylated (Supplementary Fig. <xref rid="MOESM1" ref-type="media">6</xref>). The intermediates <bold>3a</bold> and <bold>3b</bold> are then cleaved by CgnD to release the core scaffold and make the N terminus available for methylation by CgnL. It remains unclear if <italic>N</italic>-methylation or carbamoylation occurs first, or whether both modifications are independent of each other, since the <italic>des</italic>-carbamoyl <bold>1</bold> can be observed after knocking out <italic>cgnI</italic> in vivo<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>. It is also possible that carbamoylation occurs prior to leader peptide cleavage, which would offer an alternative explanation for the slow turnover of CgnD that we observed.</p><p id="Par27">CgnE appears to recruit the substrate peptide CgnA to CgnC and assist in catalysis, perhaps by presenting the core peptide in a specific conformation or by ensuring appropriate timing of the hydroxylation reactions, but does not seem to possess catalytic activity itself. The CgnE homologue CgnB on the other hand appears to possess catalytic activity. Unfortunately, all attempts to obtain crystal structures of CgnA&#x02013;CgnB or CgnA&#x02013;CgnE complexes, which would reveal more details of the interactions, failed. A search for CgnB and CgnE in available genomic data places them in a variety of genomes that warrant further investigation. In all cases where two copies were found, they were placed in a crocagin-like BGC with a CgnC homologue, and we thus expect them to install the hallmark tetracyclic core. While these BGCs also contained a methyltransferase, likely to cap the N terminus as observed in crocagins, we were surprised by the variety of different putative modifying enzymes. These may be used for the modification of the hydroxyl group found at the Trp C&#x003b2; (glycosylation), the Trp carboxy group (decarboxylation) or the Tyr hydroxyl group. Further studies will be required to identify the natural products of these BGCs, explore their bioactivities and link predicted open reading frames to biosynthetic functions. Interestingly, the gene annotated as G in the BGC identified in <italic>Anabaena</italic> (Fig. <xref rid="Fig3" ref-type="fig">3d</xref>) shares 61% sequence identity with a bifunctional 6&#x02032;-aminoglycoside-<italic>N</italic>-acetyltransferase/aminoglycoside-2&#x02032;-phosphotransferase<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>, which confers broad-spectrum resistance to aminoglycoside antibiotics. It may serve as a self-resistance gene and hint at the bioactivity of glycosylated crocagin derivatives.</p><p id="Par28">It will be fascinating to investigate the crocagin biosynthetic system in more detail, as these data could then be used in conjunction with enzymes from the newly discovered crocagin-like BGCs to access a structurally diverse family of peptide-derived pyrroloindoline alkaloids.</p></sec><sec id="Sec11"><title>Methods</title><p id="Par29">The <xref rid="MOESM1" ref-type="media">Supplementary Methods</xref> contain additional information on protein purification, production, crystallography and biophysical and biochemical methods, as well as bioinformatics.</p><sec id="Sec12"><title>Protein purification of CgnB, CgnC, CgnD, CgnE and CgnL</title><p id="Par30">For protein purification, the cell pellets were resuspended in the respective lysis buffers (for CgnD and CgnE, 500&#x02009;mM NaCl, 20&#x02009;mM Tris buffer with pH 8.0, 20&#x02009;mM imidazole, 3&#x02009;mM &#x003b2;-mercaptoethanol; for CgnB, CgnC and CgnL, 200&#x02009;mM NaCl, 20&#x02009;mM Tris, 20&#x02009;mM imidazole, 10% glycerol, 3&#x02009;mM &#x003b2;-mercaptoethanol). For every 25&#x02009;g of wet cell mass, 100&#x02009;ml of lysis buffer was added and supplemented with two cOmplete ethylenediaminetetraacetic-acid-free protease inhibitor tablets (Sigma-Aldrich) and 4&#x02009;mg&#x02009;g<sup>&#x02212;1</sup> DNase (Sigma-Aldrich). Cell lysis was carried out via passage through a cell disruptor (30&#x02009;kpsi, Constant Systems), and the cell debris was removed by centrifugation (43,000<italic>g</italic>, 15&#x02009;min, 4&#x02009;&#x000b0;C). The supernatant was decanted, filtered through a 0.45&#x02009;&#x000b5;m filter and applied to a HisTrap HP 5&#x02009;ml column (GE Healthcare) pre-equilibrated in lysis buffer at a flow rate of 5&#x02009;ml&#x02009;min<sup>&#x02212;1</sup>. The column was extensively washed with 150&#x02009;ml lysis buffer, and the target protein was eluted using lysis buffer supplemented with 250&#x02009;mM imidazole. The proteins were passed over a desalting column (16/10, GE Healthcare) at a flow rate of 10&#x02009;ml&#x02009;min<sup>&#x02212;1</sup>, pre-equilibrated in lysis buffer. To remove the His-SUMO tag, the desalted protein was incubated with TEV protease for 14&#x02009;h and 4&#x02009;&#x000b0;C at a 1:10 mass ratio of TEV/target-protein. Subsequent passage of the solution over a 5&#x02009;ml HisTrap HP column allowed for a separation of the digested target protein and the His<sub>6</sub>-tagged SUMO. The proteins were then passed over a Superdex 200 16/600 size-exclusion column (GE Healthcare) at a flow rate of 1&#x02009;ml&#x02009;min<sup>&#x02212;1</sup>, pre-equilibrated in gel filtration buffer (150&#x02009;mM NaCl, 10&#x02009;mM HEPES buffer, 0.5&#x02009;mM TCEP reducing agent, pH 7.4). The resulting peak was collected and concentrated to the desired concentration using a 30&#x02009;kDa cut-off filter (Thermo Scientific). The protein concentration was determined using photometric analysis (Nanodrop 2000, Thermo Scientific) and subsequently analysed by sodium dodecyl-sulfate polyacrylamide gel electrophoresis. Selenomethionine variants of CgnD and CgnE were purified analogously to the native proteins.</p></sec><sec id="Sec13"><title>Biochemical reactions</title><p id="Par31">All biochemical reactions were performed in 150&#x02009;mM NaCl, 10&#x02009;mM HEPES, 0.5&#x02009;mM TCEP, pH 7.4. For CgnA&#x02013;CgnB&#x02013;CgnC reactions, a mixture of 50&#x02009;&#x000b5;M CgnA, 10&#x02009;&#x000b5;M CgnB, 5&#x02009;&#x000b5;M CgnC, 4&#x02009;mM ascorbic acid, 2.5&#x02009;mM FeCl<sub>2</sub> and 1&#x02009;mM 2-oxoglutaric acid was incubated at 37&#x02009;&#x000b0;C for 2&#x02009;h. For CgnA&#x02013;CgnB&#x02013;CgnC&#x02013;CgnE reactions, a mixture of 50&#x02009;&#x000b5;M CgnA, 10&#x02009;&#x000b5;M CgnB, 5&#x02009;&#x000b5;M CgnC, 5&#x02009;&#x000b5;M CgnE, 4&#x02009;mM ascorbic acid, 2.5&#x02009;mM FeCl<sub>2</sub> and 1&#x02009;mM 2-oxoglutaric acid was incubated at 37&#x02009;&#x000b0;C for 2&#x02009;h. The standard reaction volume was 50&#x02009;&#x000b5;l. Proteins were precipitated by adding 50% acetonitrile and freezing the mixture at &#x02212;80&#x02009;&#x000b0;C for 2&#x02009;h prior to liquid chromatography and mass spectrometry (LC-MS) analysis.</p><p id="Par32">CgnD activity was analysed by adding 20&#x02009;&#x000b5;M CgnD to a 100&#x02009;&#x000b5;M solution of purified <bold>3a</bold> and <bold>3b</bold> and incubating this mixture at 37&#x02009;&#x000b0;C for up to 96&#x02009;h. Remaining enzyme was precipitated by adding 50% acetonitrile and freezing the mixture at &#x02212;80&#x02009;&#x000b0;C for 2&#x02009;h prior to LC-MS analysis. CgnL reaction was performed by adding 20&#x02009;&#x000b5;M CgnL to 100&#x02009;&#x000b5;M <bold>4a</bold> and 4<bold>b</bold> (product of CgnD reaction), supplemented by 1&#x02009;mM <italic>S</italic>-adenosyl-<sc>l</sc>-methionine and 1&#x02009;mM MgCl<sub>2</sub>. The mixture was incubated at room temperature for 24&#x02009;h. Remaining enzyme was precipitated by adding 50% acetonitrile and freezing the mixture at &#x02212;80&#x02009;&#x000b0;C for 2&#x02009;h prior to LC-MS analysis.</p><p id="Par33">For large-scale purification of <bold>3a</bold> and <bold>3b</bold>, three 9&#x02009;ml reactions of the aforementioned condition were pooled and precipitated by addition of 50% acetonitrile and the mixture being frozen at &#x02212;80&#x02009;&#x000b0;C for 16&#x02009;h. Thawed samples were centrifuged at 3,000<italic>g</italic> for 20&#x02009;min at room temperature. The supernatant was removed and sent to Protein Peptide Research for high-performance liquid chromatography purification.</p></sec><sec id="Sec14"><title>Reporting summary</title><p id="Par34">Further information on research design is available in the <xref rid="MOESM2" ref-type="media">Nature Portfolio Reporting Summary</xref> linked to this article.</p></sec></sec><sec id="Sec15" sec-type="materials|methods"><title>Online content</title><p id="Par35">Any methods, additional references, Nature Portfolio reporting summaries, source data, extended data for the sequence similarity network, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at 10.1038/s41557-023-01153-w.</p></sec><sec sec-type="supplementary-material"><title>Supplementary information</title><sec id="Sec16"><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41557_2023_1153_MOESM1_ESM.pdf"><label>Supplementary Information</label><caption><p>Supplementary Figs. 1&#x02013;24, Tables 1&#x02013;8 and Methods.</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="41557_2023_1153_MOESM2_ESM.pdf"><caption><p>Reporting Summary</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="41557_2023_1153_MOESM3_ESM.pdf"><label>Supplementary Data 1</label><caption><p>Phylogenetic tree of CgnB and CgnE homologues with accession codes.</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM4"><media xlink:href="41557_2023_1153_MOESM4_ESM.xlsx"><label>Supplementary Table 1</label><caption><p>Detailed data for sequence similarity network in Supplementary Fig. 15 (sheet 1). List of reagents and primer (sheet 2).</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM5"><media xlink:href="41557_2023_1153_MOESM5_ESM.zip"><label>Supplementary Code 1</label><caption><p>Custom scripts used for genome mining in this study.</p></caption></media></supplementary-material>
</p></sec></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><sec><title>Supplementary information</title><p>The online version contains supplementary material available at 10.1038/s41557-023-01153-w.</p></sec><ack><title>Acknowledgements</title><p>This work was supported by the European Research Council (Consolidator Grant 101002326 to J.K.). We are grateful for A. Heckmanns&#x02019;s help with the knockout studies and to V. Olive at the Scottish Universities Environmental Research Centre for ICP-MS analysis. We acknowledge the College of Medical, Veterinary &#x00026; Life Sciences Structural Biology and Biophysical Characterisation Facility, University of Glasgow, for the use of Microscale Thermophoresis. We thank J. Prunet and A. Jamieson for helpful discussions, M. Molinari for help running RiPPER and D. France and M. Groll for critical reading of the paper.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>S.A., A.K., D.Z., C.V., R.M. and J.K. designed the study. C.V. and R.M. oversaw and analysed the <italic>cgnE</italic> knockout data; S.A. and A.K. established and optimized protein production. S.A., A.K. and D.Z. performed and analysed biochemical experiments. S.A., A.K., D.Z. and J.K. determined and analysed the protein crystal structures. S.L.S. recorded and interpreted MS<sup>2</sup> data. S.A. and W.M. recorded and interpreted mass spectrometry data. O.V.K. was responsible for the bioinformatics analysis. B.O.S. acquired and interpreted the NMR data. S.A., O.V.K., R.M. and J.K. wrote the paper.</p></notes><notes notes-type="peer-review"><title>Peer review</title><sec id="FPar1"><title>Peer review information</title><p id="Par36"><italic>Nature Chemistry</italic> thanks Yanyan Li, Satish Nair and Weixin Tang for their contribution to the peer review of this work.</p></sec></notes><notes notes-type="data-availability"><title>Data availability</title><p>Data supporting the main findings of this work are available within the Article and Supplementary Information. Diffraction data and refined structural models (Supplementary Table <xref rid="MOESM1" ref-type="media">3</xref>) have been deposited to the PDB: CgnB (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2210/pdb6zsv/pdb">6zsv</ext-link>), CgnD (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2210/pdb8a2n/pdb">8a2n</ext-link>), CgnE (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2210/pdb6zsu/pdb">6zsu</ext-link>) and CgnL (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2210/pdb7pd7/pdb">7pd7</ext-link>). The very large raw mass spectrometry data files are available from the authors upon request.</p></notes><notes notes-type="data-availability"><title>Code availability</title><p>The code/scripts used for genome mining are available in Supplementary Code <xref rid="MOESM5" ref-type="media">1</xref>.</p></notes><notes id="FPar2" notes-type="COI-statement"><title>Competing interests</title><p id="Par37">The authors declare no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demain</surname><given-names>AL</given-names></name></person-group><article-title>Antibiotics: natural products essential to human health</article-title><source>Med. Res. Rev.</source><year>2009</year><volume>29</volume><fpage>821</fpage><lpage>842</lpage><pub-id pub-id-type="doi">10.1002/med.20154</pub-id><?supplied-pmid 19291695?><pub-id pub-id-type="pmid">19291695</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hutchings</surname><given-names>MI</given-names></name><name><surname>Truman</surname><given-names>AW</given-names></name><name><surname>Wilkinson</surname><given-names>B</given-names></name></person-group><article-title>Antibiotics: past, present and future</article-title><source>Curr. Opin. Microbiol.</source><year>2019</year><volume>51</volume><fpage>72</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/j.mib.2019.10.008</pub-id><?supplied-pmid 31733401?><pub-id pub-id-type="pmid">31733401</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Repka</surname><given-names>LM</given-names></name><name><surname>Reisman</surname><given-names>SE</given-names></name></person-group><article-title>Recent developments in the catalytic, asymmetric construction of pyrroloindolines bearing all-carbon quaternary stereocenters</article-title><source>J. Org. Chem.</source><year>2013</year><volume>78</volume><fpage>12314</fpage><lpage>12320</lpage><pub-id pub-id-type="doi">10.1021/jo4017953</pub-id><?supplied-pmid 24295135?><pub-id pub-id-type="pmid">24295135</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruiz-Sanchis</surname><given-names>P</given-names></name><name><surname>Savina</surname><given-names>SA</given-names></name><name><surname>Albericio</surname><given-names>F</given-names></name><name><surname>Alvarez</surname><given-names>M</given-names></name></person-group><article-title>Structure, bioactivity and synthesis of natural products with hexahydropyrrolo[2,3-<italic>b</italic>]indole</article-title><source>Chemistry</source><year>2011</year><volume>17</volume><fpage>1388</fpage><lpage>1408</lpage><pub-id pub-id-type="doi">10.1002/chem.201001451</pub-id><?supplied-pmid 21268138?><pub-id pub-id-type="pmid">21268138</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mei</surname><given-names>GJ</given-names></name><name><surname>Koay</surname><given-names>WL</given-names></name><name><surname>Tan</surname><given-names>CXA</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name></person-group><article-title>Catalytic asymmetric preparation of pyrroloindolines: strategies and applications to total synthesis</article-title><source>Chem. Soc. Rev.</source><year>2021</year><volume>50</volume><fpage>5985</fpage><lpage>6012</lpage><pub-id pub-id-type="doi">10.1039/D0CS00530D</pub-id><?supplied-pmid 34027944?><pub-id pub-id-type="pmid">34027944</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>W</given-names></name><etal/></person-group><article-title>Efficient biosynthesis of heterodimeric C<sup>3</sup>-aryl pyrroloindoline alkaloids</article-title><source>Nat. Commun.</source><year>2018</year><volume>9</volume><fpage>4428</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-06528-z</pub-id><?supplied-pmid 30356123?><pub-id pub-id-type="pmid">30356123</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saruwatari</surname><given-names>T</given-names></name><etal/></person-group><article-title>Cytochrome P450 as dimerization catalyst in diketopiperazine alkaloid biosynthesis</article-title><source>ChemBioChem</source><year>2014</year><volume>15</volume><fpage>656</fpage><lpage>659</lpage><pub-id pub-id-type="doi">10.1002/cbic.201300751</pub-id><?supplied-pmid 24677498?><pub-id pub-id-type="pmid">24677498</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>CY</given-names></name><etal/></person-group><article-title>Biosynthesis of complex indole alkaloids: elucidation of the concise pathway of okaramines</article-title><source>Angew. Chem. Int. Ed.</source><year>2017</year><volume>56</volume><fpage>9478</fpage><lpage>9482</lpage><pub-id pub-id-type="doi">10.1002/anie.201705501</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>J</given-names></name><etal/></person-group><article-title>Biosynthesis of himastatin: assembly line and characterization of three cytochrome P450 enzymes involved in the post-tailoring oxidative steps</article-title><source>Angew. Chem. Int. Ed.</source><year>2011</year><volume>50</volume><fpage>7797</fpage><lpage>7802</lpage><pub-id pub-id-type="doi">10.1002/anie.201102305</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><etal/></person-group><article-title>Pyrroloindoline cyclization in tryptophan-containing cyclodipeptides mediated by an unprecedented indole C3 methyltransferase from <italic>Streptomyces</italic> sp. HPH0547</article-title><source>Chem. Commun.</source><year>2019</year><volume>55</volume><fpage>8390</fpage><lpage>8393</lpage><pub-id pub-id-type="doi">10.1039/C9CC03745D</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Ng</surname><given-names>T</given-names></name><name><surname>Rui</surname><given-names>Z</given-names></name><name><surname>Ad</surname><given-names>O</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name></person-group><article-title>Unusual acetylation-dependent reaction cascade in the biosynthesis of the pyrroloindole drug physostigmine</article-title><source>Angew. Chem. Int. Ed.</source><year>2014</year><volume>53</volume><fpage>136</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1002/anie.201308069</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haynes</surname><given-names>SW</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Tang</surname><given-names>Y</given-names></name><name><surname>Walsh</surname><given-names>CT</given-names></name></person-group><article-title>Complexity generation in fungal peptidyl alkaloid biosynthesis: a two-enzyme pathway to the hexacyclic MDR export pump inhibitor ardeemin</article-title><source>ACS Chem. Biol.</source><year>2013</year><volume>8</volume><fpage>741</fpage><lpage>748</lpage><pub-id pub-id-type="doi">10.1021/cb3006787</pub-id><?supplied-pmid 23330675?><pub-id pub-id-type="pmid">23330675</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>WB</given-names></name><name><surname>Grundmann</surname><given-names>A</given-names></name><name><surname>Cheng</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>SM</given-names></name></person-group><article-title>Acetylaszonalenin biosynthesis in <italic>Neosartorya fischeri</italic>. Identification of the biosynthetic gene cluster by genomic mining and functional proof of the genes by biochemical investigation</article-title><source>J. Biol. Chem.</source><year>2009</year><volume>284</volume><fpage>100</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1074/jbc.M807606200</pub-id><?supplied-pmid 19001367?><pub-id pub-id-type="pmid">19001367</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>T</given-names></name><etal/></person-group><article-title>Genome mining of cyclodipeptide synthases unravels unusual tRNA-dependent diketopiperazine-terpene biosynthetic machinery</article-title><source>Nat. Commun.</source><year>2018</year><volume>9</volume><fpage>4091</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-06411-x</pub-id><?supplied-pmid 30291234?><pub-id pub-id-type="pmid">30291234</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montalban-Lopez</surname><given-names>M</given-names></name><etal/></person-group><article-title>New developments in RiPP discovery, enzymology and engineering</article-title><source>Nat. Prod. Rep.</source><year>2020</year><volume>38</volume><fpage>130</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1039/D0NP00027B</pub-id><?supplied-pmid 32935693?><pub-id pub-id-type="pmid">32935693</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnison</surname><given-names>PG</given-names></name><etal/></person-group><article-title>Ribosomally synthesized and post-translationally modified peptide natural products: overview and recommendations for a universal nomenclature</article-title><source>Nat. Prod. Rep.</source><year>2013</year><volume>30</volume><fpage>108</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1039/C2NP20085F</pub-id><?supplied-pmid 23165928?><pub-id pub-id-type="pmid">23165928</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McIntosh</surname><given-names>JA</given-names></name><name><surname>Donia</surname><given-names>MS</given-names></name><name><surname>Schmidt</surname><given-names>EW</given-names></name></person-group><article-title>Ribosomal peptide natural products: bridging the ribosomal and nonribosomal worlds</article-title><source>Nat. Prod. Rep.</source><year>2009</year><volume>26</volume><fpage>537</fpage><lpage>559</lpage><pub-id pub-id-type="doi">10.1039/b714132g</pub-id><?supplied-pmid 19642421?><pub-id pub-id-type="pmid">19642421</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walsh</surname><given-names>CT</given-names></name></person-group><article-title>Blurring the lines between ribosomal and nonribosomal peptide scaffolds</article-title><source>ACS Chem. Biol.</source><year>2014</year><volume>9</volume><fpage>1653</fpage><lpage>1661</lpage><pub-id pub-id-type="doi">10.1021/cb5003587</pub-id><?supplied-pmid 24883916?><pub-id pub-id-type="pmid">24883916</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hudson</surname><given-names>GA</given-names></name><name><surname>Mitchell</surname><given-names>DA</given-names></name></person-group><article-title>RiPP antibiotics: biosynthesis and engineering potential</article-title><source>Curr. Opin. Microbiol.</source><year>2018</year><volume>45</volume><fpage>61</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1016/j.mib.2018.02.010</pub-id><?supplied-pmid 29533845?><pub-id pub-id-type="pmid">29533845</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>B&#x000fc;chel</surname><given-names>E</given-names></name><name><surname>Martini</surname><given-names>U</given-names></name><name><surname>Mayer</surname><given-names>A</given-names></name><name><surname>Anke</surname><given-names>H</given-names></name><name><surname>Sterner</surname><given-names>O</given-names></name></person-group><article-title>Omphalotins B, C and D, nematicidal cyclopeptides from <italic>Omphalotus olearius</italic>. Absolute configuration of omphalotin A</article-title><source>Tetrahedron</source><year>1998</year><volume>54</volume><fpage>5345</fpage><lpage>5352</lpage><pub-id pub-id-type="doi">10.1016/S0040-4020(98)00209-9</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okada</surname><given-names>M</given-names></name><etal/></person-group><article-title>Structure of the <italic>Bacillus subtilis</italic> quorum-sensing peptide pheromone ComX</article-title><source>Nat. Chem. Biol.</source><year>2005</year><volume>1</volume><fpage>23</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1038/nchembio709</pub-id><?supplied-pmid 16407988?><pub-id pub-id-type="pmid">16407988</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishida</surname><given-names>K</given-names></name><name><surname>Matsuda</surname><given-names>H</given-names></name><name><surname>Murakami</surname><given-names>M</given-names></name><name><surname>Yamaguchi</surname><given-names>K</given-names></name></person-group><article-title>Kawaguchipeptin A, a novel cyclic undecapeptide from cyanobacterium <italic>Microcystis aeruginosa</italic> (NIES-88)</article-title><source>Tetrahedron</source><year>1996</year><volume>52</volume><fpage>9025</fpage><lpage>9030</lpage><pub-id pub-id-type="doi">10.1016/0040-4020(96)00452-8</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okada</surname><given-names>M</given-names></name><name><surname>Sugita</surname><given-names>T</given-names></name><name><surname>Abe</surname><given-names>I</given-names></name></person-group><article-title>Posttranslational isoprenylation of tryptophan in bacteria</article-title><source>Beilstein J. Org. Chem.</source><year>2017</year><volume>13</volume><fpage>338</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.3762/bjoc.13.37</pub-id><?supplied-pmid 28326143?><pub-id pub-id-type="pmid">28326143</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viehrig</surname><given-names>K</given-names></name><etal/></person-group><article-title>Structure and biosynthesis of crocagins: polycyclic posttranslationally modified ribosomal peptides from <italic>Chondromyces crocatus</italic></article-title><source>Angew. Chem. Int. Ed.</source><year>2017</year><volume>56</volume><fpage>7407</fpage><lpage>7410</lpage><pub-id pub-id-type="doi">10.1002/anie.201612640</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maurer</surname><given-names>CK</given-names></name><etal/></person-group><article-title>Discovery of the first small-molecule CsrA&#x02013;RNA interaction inhibitors using biophysical screening technologies</article-title><source>Future Med. Chem.</source><year>2016</year><volume>8</volume><fpage>931</fpage><lpage>947</lpage><pub-id pub-id-type="doi">10.4155/fmc-2016-0033</pub-id><?supplied-pmid 27253623?><pub-id pub-id-type="pmid">27253623</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heroven</surname><given-names>AK</given-names></name><name><surname>Bohme</surname><given-names>K</given-names></name><name><surname>Dersch</surname><given-names>P</given-names></name></person-group><article-title>The Csr/Rsm system of Yersinia and related pathogens: a post-transcriptional strategy for managing virulence</article-title><source>RNA Biol.</source><year>2012</year><volume>9</volume><fpage>379</fpage><lpage>391</lpage><pub-id pub-id-type="doi">10.4161/rna.19333</pub-id><?supplied-pmid 22336760?><pub-id pub-id-type="pmid">22336760</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vakulskas</surname><given-names>CA</given-names></name><name><surname>Potts</surname><given-names>AH</given-names></name><name><surname>Babitzke</surname><given-names>P</given-names></name><name><surname>Ahmer</surname><given-names>BM</given-names></name><name><surname>Romeo</surname><given-names>T</given-names></name></person-group><article-title>Regulation of bacterial virulence by Csr (Rsm) systems</article-title><source>Microbiol. Mol. Biol. Rev.</source><year>2015</year><volume>79</volume><fpage>193</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1128/MMBR.00052-14</pub-id><?supplied-pmid 25833324?><pub-id pub-id-type="pmid">25833324</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hildebrand</surname><given-names>A</given-names></name><name><surname>Remmert</surname><given-names>M</given-names></name><name><surname>Biegert</surname><given-names>A</given-names></name><name><surname>Soding</surname><given-names>J</given-names></name></person-group><article-title>Fast and accurate automatic structure prediction with HHpred</article-title><source>Proteins</source><year>2009</year><volume>77</volume><fpage>128</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1002/prot.22499</pub-id><?supplied-pmid 19626712?><pub-id pub-id-type="pmid">19626712</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>H</given-names></name><etal/></person-group><article-title>CheckMyMetal: a macromolecular metal-binding validation tool</article-title><source>Acta Crystallogr. D Struct. Biol.</source><year>2017</year><volume>73</volume><fpage>223</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1107/S2059798317001061</pub-id><?supplied-pmid 28291757?><pub-id pub-id-type="pmid">28291757</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holm</surname><given-names>L</given-names></name></person-group><article-title>Using Dali for protein structure comparison</article-title><source>Methods Mol. Biol.</source><year>2020</year><volume>2112</volume><fpage>29</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1007/978-1-0716-0270-6_3</pub-id><?supplied-pmid 32006276?><pub-id pub-id-type="pmid">32006276</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santos-Aberturas</surname><given-names>J</given-names></name><etal/></person-group><article-title>Uncovering the unexplored diversity of thioamidated ribosomal peptides in Actinobacteria using the RiPPER genome mining tool</article-title><source>Nucleic Acids Res.</source><year>2019</year><volume>47</volume><fpage>4624</fpage><lpage>4637</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz192</pub-id><?supplied-pmid 30916321?><pub-id pub-id-type="pmid">30916321</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Houssen</surname><given-names>WE</given-names></name><etal/></person-group><article-title>The discovery of new cyanobactins from <italic>Cyanothece</italic> PCC 7425 defines a new signature for processing of patellamides</article-title><source>ChemBioChem</source><year>2012</year><volume>13</volume><fpage>2683</fpage><lpage>2689</lpage><pub-id pub-id-type="doi">10.1002/cbic.201200661</pub-id><?supplied-pmid 23169461?><pub-id pub-id-type="pmid">23169461</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bauer</surname><given-names>J</given-names></name><etal/></person-group><article-title>Structure and possible mechanism of the CcbJ methyltransferase from <italic>Streptomyces caelestis</italic></article-title><source>Acta Crystallogr. D Biol. Crystallogr.</source><year>2014</year><volume>70</volume><fpage>943</fpage><lpage>957</lpage><pub-id pub-id-type="doi">10.1107/S139900471303397X</pub-id><?supplied-pmid 24699640?><pub-id pub-id-type="pmid">24699640</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delvaux</surname><given-names>NA</given-names></name><name><surname>Thoden</surname><given-names>JB</given-names></name><name><surname>Holden</surname><given-names>HM</given-names></name></person-group><article-title>Molecular architecture of KedS8, a sugar <italic>N</italic>-methyltransferase from <italic>Streptoalloteichus</italic> sp. ATCC 53650</article-title><source>Protein Sci.</source><year>2015</year><volume>24</volume><fpage>1593</fpage><lpage>1599</lpage><pub-id pub-id-type="doi">10.1002/pro.2742</pub-id><?supplied-pmid 26177844?><pub-id pub-id-type="pmid">26177844</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Czekster</surname><given-names>CM</given-names></name><name><surname>Ge</surname><given-names>Y</given-names></name><name><surname>Naismith</surname><given-names>JH</given-names></name></person-group><article-title>Mechanisms of cyanobactin biosynthesis</article-title><source>Curr. Opin. Chem. Biol.</source><year>2016</year><volume>35</volume><fpage>80</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.cbpa.2016.08.029</pub-id><?supplied-pmid 27639115?><pub-id pub-id-type="pmid">27639115</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jordan</surname><given-names>PA</given-names></name><name><surname>Moore</surname><given-names>BS</given-names></name></person-group><article-title>Biosynthetic pathway connects cryptic ribosomally synthesized posttranslationally modified peptide genes with pyrroloquinoline alkaloids</article-title><source>Cell Chem. Biol.</source><year>2016</year><volume>23</volume><fpage>1504</fpage><lpage>1514</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2016.10.009</pub-id><?supplied-pmid 27866908?><pub-id pub-id-type="pmid">27866908</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>CA</given-names></name><name><surname>Toth</surname><given-names>M</given-names></name><name><surname>Weiss</surname><given-names>TM</given-names></name><name><surname>Frase</surname><given-names>H</given-names></name><name><surname>Vakulenko</surname><given-names>SB</given-names></name></person-group><article-title>Structure of the bifunctional aminoglycoside-resistance enzyme AAC(6&#x02032;)-Ie-APH(2&#x02033;)-Ia revealed by crystallographic and small-angle X-ray scattering analysis</article-title><source>Acta Crystallogr. D Biol. Crystallogr.</source><year>2014</year><volume>70</volume><fpage>2754</fpage><lpage>2764</lpage><pub-id pub-id-type="doi">10.1107/S1399004714017635</pub-id><?supplied-pmid 25286858?><pub-id pub-id-type="pmid">25286858</pub-id></element-citation></ref></ref-list></back></article>